Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy

Prostate

Volumn 61, Issue 1, 2004, Pages 12-25

  Ma, Qiangzhong ^a   Safar, Mazin ^a   Holmes, Eric ^b   Wang, Yawen ^a   Boynton, Alton L ^b   Junghans, Richard P ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NORTHWEST HOSPITAL   (United States)

^c HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

Adoptive immunotherapy; Chimeric immunoglobulin T cell receptor; Designer T cells; Gene therapy; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3D8; PROSTATE SPECIFIC MEMBRANE ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CANCER INHIBITION; CHIMERA; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; GENE THERAPY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE ACTIVATION; TARGET CELL; TUMOR CELL CULTURE; TUMOR GROWTH; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; CELL LINE, TUMOR; CLONING, MOLECULAR; CYTOTOXICITY TESTS, IMMUNOLOGIC; FLOW CYTOMETRY; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PRECIPITIN TESTS; PROSTATIC NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 4143084967     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20073     Document Type: Article

References (69)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Gregorakis AK, Holmes EH, Murphy GP. Prostate-specific membrane antigen: Current and future utility. Semin Urol Oncol 1998;16:2-12.
3. Maraj BH, Whelan P, Markham AF. Prostate-specific membrane antigen. Br J Urol 1998;81:523-528.
4. Junghans RP, Sgouros G, Scheinberg D. Antibody-based immunotherapies for cancer. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: Principles and practice. PA: Lippincott; 1996. pp 655-689.
5. Rosenberg SA. Principles and applications of biological therapy. In: DeVita TJ, Hellman S, Rosenberg SA, editors. Cancer: Principles and practice of oncology. Vol. V. PA: Lippincott; 1993. pp 293-324.
6. Ma Q, Gonzalo-Daganzo RM, Junghans RP. Genetically engineered T cells as adoptive immunotherapy of cancer. In: Giaccone R, Schilsky R, Sondel P, editors. Cancer chemotherapy and biological response modifers, Annual 20. UK: Elsevier Science; 2002. pp 315-341.
7. Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, Nagase F, Kurosawa Y. Expression of chimeric receptor composed of immunoglobulin- derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 1987;149:960-968.
8. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003;3:35-45.
9. Nolan KF, Yun CO, Akamatsu Y, Murphy JC, Leung SO, Beecham EJ, Junghans RP. Bypassing immunization: Optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res 1999;5:3928-3941.
10. Beecham EJ, Ortiz-Pujols S, Junghans RP. Dynamics of tumor cell killing by human T lymphocytes armed with an anti-carcinoembryonic antigen chimeric immunoglobulin T-cell receptor. J Immunother 2000;23:332-343.
11. Yun CO, Nolan KF, Beecham EJ, Reisfeld RA, Junghans RP. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia 2000;2:449-459.
12. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 1989;86:10024-10028.
13. Goverman J, Gomez SM, Segesman KD, Hunkapiller T, Laug WE, Hood L. Chimeric immunoglobulin-T cell receptor proteins form functional receptors: Implications for T cell receptor complex formation and activation. Cell 1990;60:929-939.
14. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993;90:720-724.
15. Roberts MR, Qin L, Zhang D, Smith DH, Tran AC, Dull TJ, Groopman JE, Capon DJ, Byrn RA, Finer MH. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 1994;84:2878-2889.
16. Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Pohl C, Abken H. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. Cancer Res 1998;58:1116-1119.
17. Moritz D, Wels W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 1994;91:4318-4322.
18. Hwu P, Shafer GE, Treisman J, Schindler DG, Gross G, Cowherd R, Rosenberg SA, Eshhar Z. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med 1993;178:361-366.
19. Weijtens ME, Willemsen RA, Valerio D, Stam K, Bolhuis RL. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol 1996;157:836-843.
20. Becker ML, Near R, Mudgett-Hunter M, Margolies MN, Kubo RT, Kaye J, Hedrick SM. Expression of a hybrid immunoglobulin-T cell receptor protein in transgenic mice. Cell 1989;58:911-921.
21. Altenschmidt U, Kahl R, Moritz D, Schnierle BS, Gerstmayer B, Wels W, Groner B. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. Clin Cancer Res 1996;2:1001-1008.
22. Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, Rosenberg SA. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995;55:3369-3373.
23. Altenschmidt U, Klundt E, Groner B. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression. J Immunol 1997;159:5509-5515.
24. Darcy PK, Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM, Smyth MJ. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J Immunol 2000;164:3705-3712.
25. Junghans RP, Safa M, Huberman MS, Ma Q, Ripley R, Leung S-O, Beecham EJ. Perclinical and phae I data of anti-CEA designer T cell therapy for cancer: A new immunotherapeutic modulality. Proc Am Assoc Can Res 2000;41:543.
26. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-935.
27. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993;53:227-230.
28. Wright GL Jr., Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996;48:326-334.
29. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 1998;82:2256-2261.
30. Schulke N, Varlamova OA, Donovan GP, Ma D, Gardner JP, Morrissey DM, Arrigale RR, Zhan C, Chodera AJ, Surowitz KG, Maddon PJ, Heston WD, Olson WC. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci USA 2003;100:12590-12595.
31. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA. The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980;37:115-132.
32. Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995;62:552-558.
33. Murphy GP, Tino WT, Holmes EH, Boynton AL, Erickson SJ, Bowes VA, Barren RJ, Tjoa BA, Misrock SL, Ragde H, Kenny GM. Measurement of prostate-specific membrane antigen in the serum with a new antibody. Prostate 1996;28:266-271.
34. Sramkoski RM, Pretlow TG II, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999;35:403-409.
35. Sussman JJ, Bonifacino JS, Lippincott-Schwartz J, Weissman AM, Saito T, Klausner RD, Ashwell JD. Failure to synthesize the T cell CD3-zeta chain: Structure and function of a partial T cell receptor complex. Cell 1988;52:85-95.
36. Tino WT, Huber MJ, Lake TP, Greene TG, Murphy GP, Holmes EH. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA). Hybridoma 2000;19:249-257.
37. Kroesen BJ, Mesander G, ter Haar JG, The TH, de Leij L. Direct visualisation and quantification of cellular cytotoxicity using two colour flourescence. J Immunol Methods 1992;156:47-54.
38. Piriou L, Chilmonczyk S, Genetet N, Albina E. Design of a flow cytometric assay for the determination of natural killer and cytotoxic T-lymphocyte activity in human and in different animal species. Cytometry 2000;41:289-297.
39. Luo D, Mah N, Krantz M, Wilde K, Wishart D, Zhang Y, Jacobs F, Martin L. Vl-linker-Vh orientation-dependent expression of single chain Fv-containing an engineered disulfide-stabilized bond in the framework regions. J Biochem (Tokyo) 1995;118:825-831.
40. Tsumoto K, Nakaoki Y, Ueda Y, Ogasahara K, Yutani K, Watanabe K, Kumagai I. Effect of the order of antibody variable regions on the expression of the single-chain HyHEL10 Fv fragment in E. coli and the thermodynamic analysis of its antigen-binding properties. Biochem Biophys Res Commun 1994;201:546-551.
41. Klausner RD, Lippincott-Schwartz J, Bonifacino JS. The T cell antigen receptor: Insights into organelle biology. Annu Rev Cell Biol 1990;6:403-431.
42. Johansson B, Palmer E, Bolliger L. The extracellular domain of the zeta-chain is essential for TCR function. J Immunol 1999;162:878-885.
43. Burnett FM. The concept of immunological surveillance. Progr Exp Tumor Res 1970;13:1-27.
44. Greenberg PD. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991;49:281-355.
45. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-1492.
46. Rosenberg SA. The development of new immunotherapies for the treatment of cancer using interleukin-2. A review. Ann Surg 1988;208:121-135.
47. Lafreniere R, Rosenberg SA. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J Immunol 1985;135:4273-4280.
48. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-1166.
49. Houghton AN. Cancer antigens: Immune recognition of self and altered self. J Exp Med 1994;180:1-4.
50. Boon T, Old LJ. Cancer tumor antigens. Curr Opin Immunol 1997;9:681-683.
51. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-384.
52. Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW. Antigens derived from melanocyte differentiation proteins: Self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev 2002;188:136-146.
53. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 1996;93:749-753.
54. Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, May F, Mukherjee B, Heston WD. Prostate-specific membrane antigen: A novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996;2:1445-1451.
55. Rhee MS, Wang Y, Nair MG, Galivan J. Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity. Cancer Res 1993;53:2227-2230.
56. Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell 1994;76:263-274.
57. Kearse KP, Roberts JL, Singer A. TCR alpha-CD3 delta epsilon association is the initial step in alpha beta dimer formation in murine T cells and is limiting in immature CD4+ CD8+ thymocytes. Immunity 1995;2:391-399.
58. Kearse KP, Roberts JL, Munitz TI, Wiest DL, Nakayama T, Singer A. Developmental regulation of alpha beta T cell antigen receptor expression results from differential stability of nascent TCR alpha proteins within the endoplasmic reticulum of immature and mature T cells. EMBO J 1994;13:4504-4514.
59. Kearse KP, Roberts JP, Wiest DL, Singer A. Developmental regulation of alpha beta T cell antigen receptor assembly in immature CD4+ CD8+ thymocytes. Bioessays 1995;17:1049-1054.
60. Hsi ED, Siegel JN, Minami Y, Luong ET, Klausner RD, Samelson LE. T cell activation induces rapid tyrosine phosphorylation of a limited number of cellular substrates. J Biol Chem 1989;264:10836-10842.
61. Shinkai Y, Ma A, Cheng HL, Alt FW. CD3 epsilon and CD3 zeta cytoplasmic domains can independently generate signals for T cell development and function. Immunity 1995;2:401-411.
62. Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999;1:123-127.
63. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 2002;20:70-75.
64. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-85.
65. Pinthus JH, Waks T, Kaufman-Francis K, Schindler DG, Harmelin A, Kanety H, Ramon J, Eshhar Z. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res 2003;63:2470-2476.
66. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57:3629-3634.
67. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5:2674-2681.
68. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-3198.
69. Chang SS, Reuter VE, Heston WD, Gaudin PB. Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology 2001;57:801-805.